Dana Grebeňová

631 total citations
32 papers, 528 citations indexed

About

Dana Grebeňová is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Dana Grebeňová has authored 32 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Dana Grebeňová's work include Photodynamic Therapy Research Studies (11 papers), Eosinophilic Disorders and Syndromes (4 papers) and RNA Interference and Gene Delivery (4 papers). Dana Grebeňová is often cited by papers focused on Photodynamic Therapy Research Studies (11 papers), Eosinophilic Disorders and Syndromes (4 papers) and RNA Interference and Gene Delivery (4 papers). Dana Grebeňová collaborates with scholars based in Czechia, United States and Poland. Dana Grebeňová's co-authors include Kateřina Kuželová, Zbyněk Hrkal, Iuri Marinov, Barbora Brodská, Petr Halada, Karel Smetana, Ota Fuchs, Aleš Holoubek, Petr Jarolı́m and Josef Souček and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Cellular Biochemistry.

In The Last Decade

Dana Grebeňová

31 papers receiving 527 citations

Peers

Dana Grebeňová

PRM

ONCOL

Michal Dvořák Czechia

Thirupandiyur S. Udayakumar United States

J G Levy Canada

Lai Sum Leoh United States

Irena Moserová Czechia

Neng-Yao Shih Taiwan

Dianzhong Luo China

Ella D. Reich Germany

Damien Destouches France

Xiao Hu China

Michal Dvořák Czechia

Dana Grebeňová

373 ×1.3

123 ×0.7

PRM

77 ×0.5

90 ×1.3

ONCOL

92 ×1.3

Citations per year, relative to Dana Grebeňová Dana Grebeňová (= 1×) peers Michal Dvořák

Countries citing papers authored by Dana Grebeňová

Since Specialization

Citations

This map shows the geographic impact of Dana Grebeňová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Grebeňová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Grebeňová more than expected).

Fields of papers citing papers by Dana Grebeňová

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Grebeňová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Grebeňová. The network helps show where Dana Grebeňová may publish in the future.

Co-authorship network of co-authors of Dana Grebeňová

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Grebeňová. A scholar is included among the top collaborators of Dana Grebeňová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Grebeňová. Dana Grebeňová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schnur, Rhonda E., Louisa Kalsner, Dana Grebeňová, et al.. (2024). New kinase‐deficient PAK2 variants associated with Knobloch syndrome type 2. Clinical Genetics. 106(4). 518–524. 4 indexed citations

Grebeňová, Dana, et al.. (2024). JR-AB2-011 induces fast metabolic changes independent of mTOR complex 2 inhibition in human leukemia cells. Pharmacological Reports. 76(6). 1390–1402. 1 indexed citations

Marková, Jana, et al.. (2023). A novel germline hyperactivating JAK2 mutation L604F. Annals of Hematology. 102(10). 2725–2734.

Heřman, Petr, et al.. (2021). NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization. Scientific Reports. 11(1). 10 indexed citations

Kuželová, Kateřina, et al.. (2021). Group I p21-activated kinases in leukemia cell adhesion to fibronectin. Cell Adhesion & Migration. 15(1). 18–36. 6 indexed citations

Grebeňová, Dana, et al.. (2019). PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions. Scientific Reports. 9(1). 17171–17171. 20 indexed citations

Holoubek, Aleš, et al.. (2017). Adhesion structures in leukemia cells and their regulation by Src family kinases. Cell Adhesion & Migration. 12(3). 286–298. 8 indexed citations

Kuželová, Kateřina, et al.. (2014). Group I PAK Inhibitor IPA-3 Induces Cell Death and Affects Cell Adhesivity to Fibronectin in Human Hematopoietic Cells. PLoS ONE. 9(3). e92560–e92560. 19 indexed citations

Grebeňová, Dana, et al.. (2014). Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin. PLoS ONE. 9(9). e107367–e107367. 13 indexed citations

10.

Grebeňová, Dana, Petr Halada, Daniel Rösel, et al.. (2012). Proteins implicated in the increase of adhesivity induced by suberoylanilide hydroxamic acid in leukemic cells. Journal of Proteomics. 77. 406–422. 7 indexed citations

11.

Kuželová, Kateřina, et al.. (2009). Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. Journal of Cellular Biochemistry. 109(1). 184–195. 16 indexed citations

12.

Kuželová, Kateřina, et al.. (2009). Isoform‐specific cleavage of 14‐3‐3 proteins in apoptotic JURL‐MK1 cells. Journal of Cellular Biochemistry. 106(4). 673–681. 18 indexed citations

13.

Kuželová, Kateřina, Dana Grebeňová, & Zbyněk Hrkal. (2007). Labeling of apoptotic JURL‐MK1 cells by fluorescent caspase‐3 inhibitor FAM‐DEVD‐fmk occurs mainly at site(s) different from caspase‐3 active site. Cytometry Part A. 71A(8). 605–611. 29 indexed citations

14.

Grebeňová, Dana, et al.. (2006). The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells. Blood Cells Molecules and Diseases. 37(3). 210–217. 18 indexed citations

15.

Grebeňová, Dana, et al.. (2006). Photodynamic treatment (ALA-PDT) suppresses the expression of the oncogenic Bcr-Abl kinase and affects the cytoskeleton organization in K562 cells. Journal of Photochemistry and Photobiology B Biology. 83(3). 205–212. 17 indexed citations

16.

Smetana, Karel, et al.. (2004). A Note on the Decreased Number and Loss of Fibrillar Centres in Nucleoli of Apoptotic HL-60 Leukaemic Granulocytic Precursors Produced by 5-Aminolaevulinic Acid-Based Photodynamic Treatment. Folia Biologica. 50(1). 15–20. 3 indexed citations

17.

Grebeňová, Dana, Kateřina Kuželová, Karel Smetana, et al.. (2003). Mitochondrial and endoplasmic reticulum stress-induced apoptotic pathways are activated by 5-aminolevulinic acid-based photodynamic therapy in HL60 leukemia cells. Journal of Photochemistry and Photobiology B Biology. 69(2). 71–85. 91 indexed citations

18.

Smetana, Karel, et al.. (2002). Nucleolar asynchrony observed in HL-60 leukemic granulocytic precursors resistant to 5-aminolaevulinic acid-based photodynamic treatment. Journal of Photochemistry and Photobiology B Biology. 67(3). 201–203. 2 indexed citations

19.

Grebeňová, Dana, Petr Halada, Jiří Stulík, Vladimı́r Havlı́ček, & Zbyněk Hrkal. (2000). Protein Changes in HL60 Leukemia Cells Associated with 5-Aminolevulinic Acid-based Photodynamic Therapy. Early Effects on Endoplasmic Reticulum Chaperones ¶. Photochemistry and Photobiology. 72(1). 16–16. 15 indexed citations

20.

Grebeňová, Dana, et al.. (1997). Photodynamic effects of meso-tetra(4-sulfonatophenyl) porphine on human leukemia cells HEL andHL6, human lymphocytes and bone marrow progenitor cells. Journal of Photochemistry and Photobiology B Biology. 39(3). 269–278. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact